InMed Pharmaceuticals Inc. INM Archives - Page 8 of 12

WednesdayMar 02, 2022 9:15 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) and BayMedica Rare Cannabinoids to Enter Market Q1 2022; Leveraging on Fast-Growing Global Health and Wellness Market

Over 140 rare cannabinoids exist in the cannabis plant – some with the potential to have more therapeutic benefits than those cannabinoids found prominently in the plant InMed and subsidiary BayMedica plan to release several rare cannabinoid products in the first half of 2022 Combination of complementary InMed and BayMedica business models key to increasing shareholders’ value In 2020, the global health and wellness market reached $4.436 trillion and is expected to grow at a CAGR of 5.5% from 2021 to 2030, resulting in an estimated value of $7.7 trillion by the end of the forecasted period (https://ibn.fm/BjCNi). The primary…

WednesdayFeb 16, 2022 1:47 pm

QualityStocksNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Evolution to Commercial Sales to Health and Wellness Market Featured in Research Report

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, was featured in a report published by Edison Group, a leading research and investor relations consultancy. According to the piece, InMed achieved Q222 financial results that reflect its evolution from a pure-play biotech firm to one with commercial sales to the health and wellness market, with revenues of $0.3 million, all cannabichromene (“CBC”). “As of January, it also began selling cannabicitran (‘CBT’) to the health and wellness market,” notes the report. “The now-completed BayMedica acquisition boosts its product portfolio for rare cannabinoids and rounds…

TuesdayFeb 15, 2022 12:31 pm

QualityStocksNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Names BayMedica VP of Sales, Releases Q2 2022 Report

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has appointed Gerard (Jerry) P. Griffin III as vice president of sales and marketing at BayMedica, a wholly owned subsidiary of InMed. In his new role, Griffin will manage the commercialization of BayMedica’s health and wellness business including existing products as well as the launch of new products. Griffin brings a rich background to this position, having a proven track record as a veteran sales executive. He has served in several senior positions in Fortune 500 companies, including most recently as VP of sales…

MondayFeb 14, 2022 2:22 pm

QualityStocksNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) in Unique Position to Offer Full Slate of Rare Cannabinoid Manufacturing Technologies

InMed Pharmaceuticals (NASDAQ: INM) understands the immense potential of rare cannabinoids and sees them as having applications as wide as cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”), variants of cannabinoids that make up most of the content in cannabis plants. Studies suggest that rare cannabinoids could offer more potent medical benefits than CBD and without the psychoactive attribute of THC, representing a huge market. “However, the industry wide problem has always been to obtain the production scales necessary for cost-effective commercialization of such compounds, while also ensuring the purity and consistency that can be difficult at even low volumes. The answer is…

ThursdayFeb 10, 2022 12:03 pm

QualityStocksNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Release Q2 Financial Report, Business Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has announced that it will report its second-quarter financial results next week on Feb. 15, 2022; the results will cover the period ending Dec. 31, 2021. The company has scheduled a conference call and webcast to discuss the report; the call will be held Feb. 15, 2021, at 2 p.m. ET. Those interested can dial +1 (855) 605-1745 (United States and Canada) or +1 (914) 987-7959 (international) using conference ID 8645175. In addition, the company’s full financial statements and related MD&A along with a replay of the…

ThursdayFeb 03, 2022 10:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Strengthens Leading Role in Rare Cannabinoid Market Following New Product Launch, Key Acquisition

Cannabicitran is the first of four new rare cannabinoids InMed is planning to launch in the first half of the year to meet growing inbound demand The launch demonstrates InMed’s ability to produce rare cannabinoids at scale, something only very few companies have achieved BayMedica acquisition, other key achievements in 2021, are positioning the company as a leading supplier of rare cannabinoids in the health and wellness sector A leader in the research, development, manufacturing and commercialization of rare cannabinoids, InMed Pharmaceuticals (NASDAQ: INM) has begun the new year from a more prominent position in the market, following key acquisitions…

WednesdayFeb 02, 2022 2:56 pm

QualityStocksNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Blazing Trail in Defining Value of Rare Cannabinoids in Pharmaceutical Space

InMed Pharmaceuticals (NASDAQ: INM) is a trailblazer, a pioneer defining the value of rare cannabinoids in the pharmaceutical sector and just how integral they are in pushing the industry forward. The global cannabis market is experiencing tremendous growth, particularly considering there are over 100 known cannabinoids, including rare ones that are quickly taking over and will soon dominate the market. The potency of rare cannabinoids has given them powerful health benefits, hence their demand within the cosmetics, food and beverage, health and wellness, and pharmaceutical sectors. “InMed’s most advanced compound, INM-755, has already proven helpful in treating epidermolysis bullosa, a…

TuesdayFeb 01, 2022 1:11 pm

InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Recent Access of Manufacturing Technologies Now Give It the Potential to Synthetically Produce Rare Cannabinoids at Large Scale, a Unique and Coveted Position in the Rapidly Developing Rare Cannabinoid Space

Rare cannabinoids are cannabinoid compounds other than CBD and THC which are not yet produced in large scale but which have potentially greater benefits InMed acquired BayMedica in October 2021, bringing on board unmatched expertise in large-scale bio-production technologies applicable to rare cannabinoids As a result of this acquisition, InMed, already a leader in the production of rare cannabinoid CBC, is now in the unique and highly desired position to undertake large-scale production of other rare cannabinoids, with applications as wide as the current CBD market The company plans to launch new rare cannabinoid products in the first half of…

WednesdayJan 26, 2022 12:15 pm

InMed Pharmaceuticals Inc. (NASDAQ: INM) Leveraging on the Growing Cannabinoid-Based Pharmaceuticals Market

The global cannabinoid-based pharmaceuticals market is projected to be valued at $50 billion by 2029 InMed is leading the industry, laying down the foundation in manufacturing and clinical development of rare cannabinoids It is shedding light on the potential of rare cannabinoids and laying the groundwork on how to tap into the industry’s growth It is projected that by 2025, the global cannabis market will be valued at around $146 billion, up from just $20.47 billion in 2020. This sector is experiencing tremendous growth, particularly considering that there are over one hundred known cannabinoids, including rare ones that are quickly…

WednesdayJan 19, 2022 12:09 pm

QualityStocksNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expands Rare Cannabinoid Product Portfolio to Launch CBT

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced that it has launched B2B sales of the rare cannabinoid cannabicitran (“CBT”) into the health and wellness sector. According to the update, CBT is the first of several new product launches the company has planned for the first half of 2022. “We are delivering on our objective to launch additional rare cannabinoids in early 2022 in response to inbound demand. By midyear, we expect to have at least four rare cannabinoids available for the health and wellness markets, positioning us as a…

Site Search

Company Search

Tag: InMed Pharmaceuticals Inc. INM